Association of host-derived vesicles with malaria severity
Accumulating evidence suggests that EVs contribute to malaria-associated clinical symptoms, in particular in severe disease (Table
1). Initial studies focused on MVs of host cell origin, largely referred to as microparticles. These host-origin MVs were associated with malaria through their role in cerebral pathogenesis, as increased levels of endothelial-derived MVs were present in patients with severe cerebral malaria [
33]. The role of MVs in malaria was further dissected using mouse models of severe disease. ABCA1 knock-out mice, which have reduced ability to produce MVs, were protected from cerebral malaria [
34]. In control mice, MVs of host platelet, monocyte and endothelial cell origins were released during infection, but this was significantly reduced in ABCA1 knock-outs. In particular, there were reduced inflammatory hallmarks such as high serum TNF and platelet and leukocyte sequestration in the brain. This in vivo work was in agreement with the association of MVs with parasite cytoadherence and their likely role in severe disease caused by parasite sequestration, particularly in cerebral malaria [
35]. The importance of ABCA1 in MV-related malaria pathogenesis was further supported by findings from a field study of human patients infected with
Plasmodium falciparum, where MV levels in patients with severe and uncomplicated malaria were tested for association with their ABCA1 promoter haplotypes [
36]. The authors reported that MV release increased during malaria infection, MV levels positively correlated to disease severity, and ABCA1 promotor genotypes were associated with susceptibility to severe malaria. These studies demonstrate that host-derived MVs were an important factor contributing to severe malaria.
Table 1
Summary of reports investigating EVs in malaria infection
Host-derived vesicles |
MV | NA | Supernatant from 13,000×g centrifugation | Endothelial | Human field study |
P. falciparum
| MVs present in infected individuals. | |
MV | NA | Supernatant from 13,000×g centrifugation | Endothelial, platelet, erythrocyte | Human field study |
P. falciparum
| MVs in infected individuals are associated with severe malaria and TNF levels. | |
MV | NA | Pellet from 100,000×g centrifugation | Endothelial, platelet, erythrocyte | Human field study |
P. falciparum
| MVs in infected individuals are associated with severe malaria and ACBA1 gene polymorphisms. | |
MV | NA | Supernatant from 13,000×g centrifugation | Endothelial, platelet, leukocyte, erythrocyte | Human field study |
P. falciparum
| MVs in infected individuals are associated with cerebral malaria only. | |
MV | NA | Pellet from 20,800×g centrifugation | Platelet | In vitro |
P. falciparum
| Platelet MVs are involved in iRBC cytoadhesion. | |
MV | NA | Pellet from 14,000×g centrifugation | Platelet, leukocyte, erythrocyte | Human field study |
P. vivax
| MVs in infected individuals are associated with malaria disease severity. | |
MV | NA | Supernatant from 13,000×g centrifugation or pellet from 20,000×g centrifugation | Endothelial, platelet, monocyte | In vivo |
P. berghei ANKA | MVs involved in cerebral malaria. | |
MV | NA | Pellet from 18,000×g centrifugation | Endothelial, platelet, erythrocyte | In vivo and in vitro |
P. berghei
| MVs localize to brain during infection, and can directly induce pathology. | |
MV | 100–1000 nm | Pellet from 18,000×g centrifugation | NA | In vivo |
P. berghei ANKA | Proteomic characterization of MVs in cerebral malaria. | |
Parasite-derived vesicles |
MV | NA | 13,000×g centrifugation | iRBC | Human field study and in vitro |
P. falciparum, P. vivax, P. malariae
| MVs released from iRBC during active infection. | |
MV | 100–400 nm | 100,000×g centrifugation on sucrose cushion | iRBC | In vitro |
P. falciparum
| MVs released from iRBC contain parasite protein and RNA, are immunostimulatory, and induce gametocytogenesis. | |
NA | NA | 100,000×g centrifugation on sucrose cushion | iRBC | In vitro |
P. falciparum
| EVs from iRBC contain functional microRNA that are endocytosed by human endothelial cells and affect barrier properties. | |
Exo | 70–120 nm | 100,000×g centrifugation on Optiprep gradient | iRBC | In vitro |
P. falciparum
| Exosomes used for intra-parasitic communication, and induce gametocytogenesis. | |
MV | 150–250 nm | Pellet from 14,000×g centrifugation | iRBC | In vivo |
P. berghei ANKA | MVs from parasites are pro-inflammatory and stimulate TLR pathways. | |
Exo | 40–80 nm | Pellet from 100,000×g centrifugation, or 100,000×g sucrose cushion | iRBC | In vivo |
P. yoelii
| iRBC release exosomes with parasite antigens; exosomes can be used to immunize naïve mice. | |
Recently, a better understanding of the content of host-derived MVs during severe malaria was achieved based on proteomic analysis of MVs from mice with cerebral malaria [
4]. There were significant changes in the protein content of MVs from
Plasmodium berghei (strain ANKA)-infected mice compared to naïve mice, and network analyses indicated that these proteins were actively involved in cerebral malaria pathogenesis. Specifically, TNF and TGFβ1 were predicted to regulate the cerebral malaria-associated proteins in MVs. These findings are in agreement with the association of MVs with cerebral malaria and the involvement of TNF in this disease [
4]. However, the field is still lacking in studies on the nucleic acid content of host-derived EVs in malaria. Transcriptomic investigations are needed to further determine if and how host-derived EVs might modulate pathogenesis in malaria, and contribute to disease severity.
Several field studies have reported increased levels of MVs during active
Plasmodium infection, analysed by flow cytometric analysis of surface stained vesicles, which returned to normal after resolution of infection. However, there have been some differences in reported MV origin, and occurrence during severe disease (Table
1). In
P. falciparum-infected patients in Cameroon, there was a significant increase in circulating MVs in patients with cerebral malaria, but not in non-cerebral severe or uncomplicated malaria, compared to controls [
37]. Platelet-derived EVs in particular were positively associated with severity of cerebral symptoms [
37]. Similar results were reported from a field study in India, where MVs originating from platelets, erythrocytes and endothelial cells were increased during infection [
38]. In this case, however, the authors reported increased MV levels in cerebral and non-cerebral severe malaria, but not in uncomplicated malaria. Furthermore, high MV levels also correlated with high serum TNF, and levels of MVs and TNF both returned to normal ranges after resolution of infection.
In addition to endothelial cells playing a central role in
P. falciparum cytoadherence and disease severity, platelet involvement in cerebral malaria is also well established [
39]. In vitro, platelet MVs can bind to
P. falciparum infected red blood cells (iRBC) in a PfEMP1-dependent manner, transfer platelet antigens to iRBC, and induce iRBC cytoadherence to endothelial cells [
40]. This has provided mechanistic insights into the involvement of MVs in cerebral malaria, suggesting that EVs can promote cerebral pathology by stimulating iRBC cytoadhesion in the brain. A recent study has investigated the fate and effect of MVs in
P. berghei-infected mice [
41]. They found that when MVs isolated from infected mice were transferred to recipient mice, these MVs localized to cerebral microvessels in infected recipient mice, but not in uninfected recipient mice. Furthermore, transfer of MVs from TNF-stimulated endothelial cells induced brain histopathology similar to cerebral malaria, indicating MVs might be active contributors to the pathologies associated with severe malaria. Notably MV localization to the brain only occurred when the recipient mice were also infected with
P. berghei, suggesting that the adhesion of these MVs to host organs requires iRBC presence/interaction.
Although most reports have focused on EVs in
P. falciparum, a study of
Plasmodium vivax infected individuals in Brazil showed that active infection was also associated with increased MV release, but these MVs originated from platelets, leukocytes and erythrocytes, and not from endothelial cells [
42]. Platelet-derived EVs in particular were correlated with high fever, suggesting these host-derived EVs might play a central role in the inflammatory symptoms of
P. vivax infection [
42]. It is interesting to note that endothelial-derived MVs were consistently found to be increased with
P. falciparum infection (Table
1), which is a cytoadhering parasite, but not with
P. vivax, which does not cytoadhere. The presence of endothelial cell MVs in
P. falciparum infection likely reflects the central involvement of this cell type in development of cytoadherent-dependent severe disease symptoms.
Placental malaria is a complication of infection caused by accumulation of iRBC in the placental intervillous space in pregnant women [
43], mediated by parasite cytoadherence. A recent study investigated potential links between host-derived MVs and placental malaria [
44]. In contrast to severe malarial anaemia or cerebral malaria, there were no changes in total MV or placental trophoblast-specific MV release in women with placental malaria compared to uninfected, indicating that although this severe disease involves parasite sequestration, host-derived MVs are not involved in this specific pathological process during pregnancy-associated malaria. However, there was an overexpression of microRNA miR-517c in MVs from malaria-infected women. miR-517 has been implicated in regulating trophoblast and placental function [
45], suggesting that MVs could have applications as biomarkers in placental malaria, and that further research is warranted.
Methodological variations in EV research could cause discrepancies
Despite several published reports, there has not been extensive characterization of host-derived MVs from humans infected with malaria. These experiments would be challenging given the high heterogeneity of human samples, but the field would benefit from a more thorough descriptive analysis of vesicles size and composition in these sample types. Furthermore, as shown in Table
1, there are discrepancies in the methodology used to isolate MVs, e.g. some studies investigate the supernatant from 13,000×
g centrifugation [
37,
38], whereas others investigate the pellets from higher centrifugation speeds [
36,
40,
41]. These differing methods of sample processing will likely result in varying compositions of the materials being investigated, and cause differing results. Furthermore, many reports did not analyse the morphology of the vesicles being studied, in particular their size, making it difficult to determine exactly what types of vesicles were investigated. Therefore, a consensus on sample preparation is required to ensure that the same vesicle types are being investigated between groups.
Despite these discrepancies, the findings of these studies collectively demonstrate that MVs are specifically released by host cells during malaria infection, and that these MVs mediate a variety of pathological effects. Their correlation with increased inflammation and iRBC cytoadherence indicates that MVs might be important causative agents of severe cerebral pathogenesis in particular. Currently, it remains difficult to determine whether malaria-associated inflammation causes increased MV release, and the MVs themselves are key mediators of pathogenesis; or if the malaria-associated pathology occurs first and the MV release is a secondary outcome of activated cells. Further work, in particular more detailed proteomic and genomic analyses of human-derived MV content, is still required to tease out effects that might be causative versus correlated between host-derived MV release and severe malaria.